The investigators induced knee osteoarthritis (KOA) in Wistar rats using intra-articular monosodium iodoacetate (MIA). The model group developed objective dysfunction: Lequesne MG scores rose, right-knee horizontal diameter increased, and pain threshold fell compared with normal controls. Both treatment arms—mild moxibustion and warm needling moxibustion—were applied at ST32 (Futu) and ST36 (Zusanli) for 30 minutes every other day over four weeks, according to the report. After intervention, animals in both groups showed lower Lequesne MG scores, smaller knee diameters, and higher pain thresholds versus the model group. The study team observed that warm needling produced greater reductions in Lequesne MG score and larger increases in pain threshold compared with mild moxibustion.
Behavioral endpoints were reported with statistical significance in the source. The article did not provide additional functional assays beyond the Lequesne MG score and the mechanical pain threshold measures documented in the abstract.
Histologic assessment used hematoxylin-eosin (HE) and safranin O staining with semiquantitative scoring by Mankin’s and OARSI systems. The model group displayed classical degenerative features: superficial cartilage layer damage and disappearance of the tidemark. Both moxibustion treatments mitigated these changes, with milder degeneration noted in the treated groups. The warm needling group had the most pronounced histologic improvement; Mankin’s and OARSI scores fell in both treatment groups versus the model, and scores in the warm needling group were significantly lower than those in the mild moxibustion group as reported by the authors.
The source lists these histologic endpoints and their comparative statistical differences; it did not present ultrastructural data or additional cartilage biomechanical testing in the abstract.
Serum assays measured interleukin-6 (IL-6), interleukin-18 (IL-18), and MMP-13 by ELISA. The model group had elevated levels of IL-6, IL-18, and MMP-13 compared with normals. Both moxibustion modalities reduced these serum markers compared with the model group; the warm needling arm achieved larger reductions for most of the reported indicators. Investigators reported statistical significance for these changes in the abstract.
These circulating marker data provide a systemic correlate to the local cartilage findings documented later in the paper. The authors did not report additional cytokines beyond those listed in the abstract, nor did they report time-course kinetics beyond the single post-intervention measurement described.
Immunohistochemistry and Western blot were performed on cartilage tissue to quantify P16INK4A, P21Waf1/Cip1, IL-6, MMP-13, and Collagen-Ⅱ. The source reports that KOA induction increased the cartilage expression of P16INK4A and P21Waf1/Cip1—proteins associated with cellular senescence—while Collagen-Ⅱ expression decreased. Both moxibustion treatments lowered cartilage P16INK4A, P21Waf1/Cip1, IL-6, and MMP-13 expression and increased Collagen-Ⅱ relative to the model group. The warm needling group showed more significant changes than the mild moxibustion group for these proteins, with the exception of joint horizontal diameter where that difference was not observed.
Those protein-level data aligned with the authors’ hypothesis that inhibition of chondrocyte senescence may be involved in the therapeutic effect. The source did not include mechanistic pathway assays (for example, signaling intermediates or senescence-associated secretory phenotype profiling) in the abstract.
The authors concluded that warm needling moxibustion improved KOA outcomes in this rat model and had superior efficacy compared with mild moxibustion. They linked the observed therapeutic effects to decreased expression of senescence markers in cartilage and to reductions in inflammatory and degradative mediators such as IL-6 and MMP-13. The report frames the mechanism as an association between treatment and inhibited chondrocyte senescence based on protein expression and histology changes.
The paper declares no conflicts of interest and provides PMID 42908455 and DOI 10.13702/j.1000-0607.20251035 for reference.
The source abstract documents a 4-week intervention and post-treatment assessments; it did not report longer-term follow-up to establish durability of effect. The report associated reduced senescence marker expression with improved histology and biomarker profiles, but it did not present molecular pathway experiments to prove causality between warm needling and senescence inhibition. The study did not report detailed dosing parameters beyond session duration and frequency in the abstract, nor did it include translational safety data for potential clinical application. These gaps identify specific unanswered questions that the published abstract leaves open for further investigation.